MLTX Quote, Financials, Valuation and Earnings

aTyr Pharma, Inc. has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -13550.53%. MoonLake Immunotherapeutics's return on equity of -53.14% beat aTyr Pharma, Inc.'s return on equity of -103.05%.

MoonLake Immunotherapeutics has a consensus price target of $14.61, signalling upside risk potential of 5.62%. On the other hand aTyr Pharma, Inc. has an analysts' consensus of $4.36 which suggests that it could grow by 486.58%. Given that aTyr Pharma, Inc. has higher upside potential than MoonLake Immunotherapeutics, analysts believe aTyr Pharma, Inc. is more attractive than MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics has a beta of 1.211, which suggesting that the stock is 21.051% more volatile than S&P 500. In comparison aTyr Pharma, Inc. has a beta of 0.572, suggesting its less volatile than the S&P 500 by 42.802%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. aTyr Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. aTyr Pharma, Inc. pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than aTyr Pharma, Inc. quarterly revenues of $190K. MoonLake Immunotherapeutics's net income of -$70.7M is lower than aTyr Pharma, Inc.'s net income of -$25.7M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while aTyr Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 348.42x for aTyr Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Baxter International, Inc. has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -1.8%. MoonLake Immunotherapeutics's return on equity of -53.14% beat Baxter International, Inc.'s return on equity of -4.83%.

MoonLake Immunotherapeutics has a consensus price target of $14.61, signalling upside risk potential of 5.62%. On the other hand Baxter International, Inc. has an analysts' consensus of $23.67 which suggests that it could grow by 22.12%. Given that Baxter International, Inc. has higher upside potential than MoonLake Immunotherapeutics, analysts believe Baxter International, Inc. is more attractive than MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics has a beta of 1.211, which suggesting that the stock is 21.051% more volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.612, suggesting its less volatile than the S&P 500 by 38.771%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International, Inc. offers a yield of 2.68% to investors and pays a quarterly dividend of $0.01 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Baxter International, Inc. quarterly revenues of $2.8B. MoonLake Immunotherapeutics's net income of -$70.7M is lower than Baxter International, Inc.'s net income of -$51M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 0.90x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merus NV has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -786.17%. MoonLake Immunotherapeutics's return on equity of -53.14% beat Merus NV's return on equity of -53.47%.

MoonLake Immunotherapeutics has a consensus price target of $14.61, signalling upside risk potential of 5.62%. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.08%. Given that MoonLake Immunotherapeutics has higher upside potential than Merus NV, analysts believe MoonLake Immunotherapeutics is more attractive than Merus NV.

MoonLake Immunotherapeutics has a beta of 1.211, which suggesting that the stock is 21.051% more volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Merus NV quarterly revenues of $12.2M. MoonLake Immunotherapeutics's net income of -$70.7M is higher than Merus NV's net income of -$95.5M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 121.83x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines Ltd. has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of 8.84%. MoonLake Immunotherapeutics's return on equity of -53.14% beat BeOne Medicines Ltd.'s return on equity of 1.92%.

MoonLake Immunotherapeutics has a consensus price target of $14.61, signalling upside risk potential of 5.62%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 28.06%. Given that BeOne Medicines Ltd. has higher upside potential than MoonLake Immunotherapeutics, analysts believe BeOne Medicines Ltd. is more attractive than MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics has a beta of 1.211, which suggesting that the stock is 21.051% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. MoonLake Immunotherapeutics's net income of -$70.7M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 601.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 6.98x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.